Retour

Aileron Therapeutics to Present at Two Upcoming Investor Conferences

Calendar Calendar of Events

AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:

GlobeNewswire Inc. • 06/05/2024 à 22:05:00
Aileron Therapeutics, Inc. Common Stock
Address: 12407 N. MOPAC EXPY.
Postal Code: 78758
City: AUSTIN
State: TX
Phone Number: (737) 802-1989
Website: https://www.aileronrx.com
Status: Active
Company Info

Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.

List Date2017-06-29
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001420565
Composite figiBBG002454KR1
Share Class figiBBG002454KS0
Market Cap79,705,283 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees15
Share Class Shares Outstanding21590000
Weighted Shares Outstanding21141985
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
3.776
3.645
3.885
3.901
3.885
Variance
3.59%
-6.18%
-0.38%
0.41%
1.7%
Open
3.645
3.885
3.9
3.885
3.82
Highest
3.885
3.994
3.975
3.965
3.918
Lowest
3.869
3.947
3.975
3.941
3.91
History
PeriodVarhighestlowest
1 week
-1.15%
3.918
3.869
1 month
-20.1%
5.4
3.731
3 month
-21.97%
4.839
3.731
6 month
91.68%
1.97
1.7469
1 year
175.62%
1.4172
1.01
3 year
-84.4%
24.6
1.01
5 year
-84.61%
24.532
1.01
10 year
-98.63%
280
1.01
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-08 2023-08-11 2023-10-13 UNPUB
Assets 17,157,000 13,991,000 12,822,000 UNPUB
Current Assets 17,105,000 13,952,000 12,793,000 UNPUB
Current Liabilities 2,884,000 1,197,000 1,624,000 UNPUB
Equity 14,273,000 12,794,000 11,198,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 14,273,000 12,794,000 11,198,000 UNPUB
Liabilities 2,884,000 1,197,000 1,624,000 UNPUB
Liabilities And Equity 17,157,000 13,991,000 12,822,000 UNPUB
Noncurrent Assets 52,000 39,000 29,000 UNPUB
Noncurrent Liabilities 0 0 0 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-08 2023-08-11 2023-10-13 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 0 UNPUB
Net Cash Flow, Continuing 0 0 0 UNPUB
Net Cash Flow From Financing Activities -2,589,000 -5,384,000 1,098,000 UNPUB
Net Cash Flow From Financing Activities, Continuing -2,589,000 -5,384,000 1,098,000 UNPUB
Net Cash Flow From Investing Activities 7,250,000 8,500,000 542,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 7,250,000 8,500,000 542,000 UNPUB
Net Cash Flow From Operating Activities -4,661,000 -3,116,000 -1,640,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -4,661,000 -3,116,000 -1,640,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-08 2023-08-11 2023-10-13 UNPUB
Comprehensive Income/Loss -4,741,000 -1,779,000 -1,825,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -4,741,000 -1,779,000 -1,825,000 UNPUB
Other Comprehensive Income/Loss 38,000 -1,779,000 -1,825,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent 38,000 8,000 2,000 UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-08 2023-08-11 2023-10-13 UNPUB
Basic Earnings Per Share -1 0 0 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -1 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -4,779,000 -1,787,000 -1,827,000 UNPUB
Income/Loss From Continuing Operations Before Tax -4,779,000 -1,787,000 -1,827,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -4,779,000 -1,787,000 -1,827,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -4,779,000 -1,787,000 -1,827,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -4,779,000 -1,787,000 -1,827,000 UNPUB
Operating Expenses 5,011,000 1,992,000 1,983,000 UNPUB
Operating Income/Loss -5,011,000 -1,992,000 -1,983,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 0 0 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-05 2022-08-15 2022-11-01 2023-03-20
Assets 40,255,000 33,770,000 27,232,000 22,007,000
Current Assets 39,993,000 33,550,000 27,054,000 21,873,000
Current Liabilities 4,146,000 5,151,000 4,536,000 3,384,000
Equity 36,109,000 28,619,000 22,696,000 18,623,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 36,109,000 28,619,000 22,696,000 18,623,000
Liabilities 4,146,000 5,151,000 4,536,000 3,384,000
Liabilities And Equity 40,255,000 33,770,000 27,232,000 22,007,000
Noncurrent Assets 262,000 220,000 178,000 134,000
Noncurrent Liabilities 0 0 0 0
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-05 2022-08-15 2022-11-01 2023-03-20
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 0 0
Net Cash Flow, Continuing 0 0 0 0
Net Cash Flow From Financing Activities -3,849,000 -179,000 2,789,000 -1,594,000
Net Cash Flow From Financing Activities, Continuing -3,849,000 -179,000 2,789,000 -1,594,000
Net Cash Flow From Investing Activities 11,649,000 5,864,000 4,182,000 26,459,000
Net Cash Flow From Investing Activities, Continuing 11,649,000 5,864,000 4,182,000 26,459,000
Net Cash Flow From Operating Activities -7,800,000 -5,685,000 -6,971,000 -24,865,000
Net Cash Flow From Operating Activities, Continuing -7,800,000 -5,685,000 -6,971,000 -24,865,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-05 2022-08-15 2022-11-01 2023-03-20
Comprehensive Income/Loss -8,422,000 -7,992,000 -6,365,000 -27,364,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -8,484,000 -8,018,000 -6,365,000 -27,364,000
Other Comprehensive Income/Loss 0 0 -6,365,000 -35,000
Other Comprehensive Income/Loss Attributable To Parent -62,000 -26,000 3,000 -35,000
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-05 2022-08-15 2022-11-01 2023-03-20
Basic Earnings Per Share 0 0 0 -6
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share 0 0 0 -6
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -8,422,000 -7,992,000 -6,368,000 -27,329,000
Income/Loss From Continuing Operations Before Tax -8,422,000 -7,992,000 -6,368,000 -27,329,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -8,422,000 -7,992,000 -6,368,000 -27,329,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -8,422,000 -7,992,000 -6,368,000 -27,329,000
Net Income/Loss Available To Common Stockholders, Basic -8,422,000 -7,992,000 -6,368,000 -27,329,000
Operating Expenses 8,421,000 8,041,000 6,482,000 27,647,000
Operating Income/Loss -8,421,000 -8,041,000 -6,482,000 -27,647,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-11 2021-11-12 2022-03-28
Assets 64,671,000 60,531,000 54,768,000 48,481,000
Current Assets 64,324,000 60,152,000 54,423,000 48,177,000
Current Liabilities 3,073,000 4,273,000 4,560,000 4,508,000
Equity 61,419,000 56,130,000 50,109,000 43,904,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 61,419,000 56,130,000 50,109,000 43,904,000
Liabilities 3,252,000 4,401,000 4,659,000 4,577,000
Liabilities And Equity 64,671,000 60,531,000 54,768,000 48,481,000
Noncurrent Assets 347,000 379,000 345,000 304,000
Noncurrent Liabilities 0 0 99,000 69,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-11 2021-11-12 2022-03-28
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 11,669,000 -8,535,000 -3,145,000 -4,014,000
Net Cash Flow, Continuing 11,669,000 -8,535,000 -3,145,000 -4,014,000
Net Cash Flow From Financing Activities 55,604,000 26,000 26,000 55,657,000
Net Cash Flow From Financing Activities, Continuing 55,604,000 26,000 26,000 55,657,000
Net Cash Flow From Investing Activities -37,459,000 -4,798,000 4,089,000 -35,917,000
Net Cash Flow From Investing Activities, Continuing -37,459,000 -4,798,000 4,089,000 -35,917,000
Net Cash Flow From Operating Activities -6,476,000 -3,763,000 -7,260,000 -23,754,000
Net Cash Flow From Operating Activities, Continuing -6,476,000 -3,763,000 -7,260,000 -23,754,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-11 2021-11-12 2022-03-28
Comprehensive Income/Loss -6,975,000 -5,686,000 -6,709,000 -26,175,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -6,980,000 -5,673,000 -6,709,000 -26,175,000
Other Comprehensive Income/Loss 0 0 -6,709,000 -11,000
Other Comprehensive Income/Loss Attributable To Parent -5,000 13,000 -5,000 -11,000
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-11 2021-11-12 2022-03-28
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -6,975,000 -5,686,000 -6,704,000 -26,164,000
Income/Loss From Continuing Operations Before Tax -6,975,000 -5,686,000 -6,704,000 -26,164,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -6,975,000 -5,686,000 -6,704,000 -26,164,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -6,975,000 -5,686,000 -6,704,000 -26,164,000
Net Income/Loss Available To Common Stockholders, Basic -6,975,000 -5,686,000 -6,704,000 -26,164,000
Operating Expenses 6,989,000 6,009,000 6,791,000 26,605,000
Operating Income/Loss -6,989,000 -6,009,000 -6,791,000 -26,605,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-05 2020-11-12 2021-03-24
Assets 20,373,000 26,125,000 22,239,000 16,341,000
Current Assets 13,687,000 19,670,000 15,974,000 16,326,000
Current Liabilities 6,143,000 4,926,000 5,249,000 3,960,000
Equity 9,769,000 16,654,000 12,458,000 12,162,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 9,769,000 16,654,000 12,458,000 12,162,000
Liabilities 10,604,000 9,471,000 9,781,000 4,179,000
Liabilities And Equity 20,373,000 26,125,000 22,239,000 16,341,000
Noncurrent Assets 6,686,000 6,455,000 6,265,000 15,000
Noncurrent Liabilities 0 0 4,532,000 219,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-05 2020-11-12 2021-03-24
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 11,813,000 -9,274,000 1,735,000
Net Cash Flow, Continuing 0 11,813,000 -9,274,000 1,735,000
Net Cash Flow From Financing Activities -5,386,000 16,646,000 298,000 15,800,000
Net Cash Flow From Financing Activities, Continuing -5,386,000 16,646,000 298,000 15,800,000
Net Cash Flow From Investing Activities 11,058,000 239,000 -4,529,000 6,411,000
Net Cash Flow From Investing Activities, Continuing 11,058,000 239,000 -4,529,000 6,411,000
Net Cash Flow From Operating Activities -5,672,000 -5,072,000 -5,043,000 -20,476,000
Net Cash Flow From Operating Activities, Continuing -5,672,000 -5,072,000 -5,043,000 -20,476,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-05 2020-11-12 2021-03-24
Comprehensive Income/Loss -6,822,000 -4,391,000 -5,022,000 -21,166,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -6,822,000 -4,391,000 -5,022,000 -21,166,000
Other Comprehensive Income/Loss -6,822,000 -4,391,000 -5,022,000 -9,000
Other Comprehensive Income/Loss Attributable To Parent -8,000 -1,000 1,000 -9,000
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-05 2020-11-12 2021-03-24
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -6,814,000 -4,390,000 -5,023,000 -21,157,000
Income/Loss From Continuing Operations Before Tax -6,814,000 -4,390,000 -5,023,000 -21,157,000
Income Tax Expense/Benefit 0 0 0 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -6,748,000 -4,390,000 -5,023,000 -21,157,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -6,814,000 -4,390,000 -5,023,000 -21,157,000
Net Income/Loss Available To Common Stockholders, Basic -6,814,000 -4,390,000 -5,023,000 -21,157,000
Operating Expenses 6,876,000 4,400,000 5,028,000 20,496,000
Operating Income/Loss -6,876,000 -4,400,000 -5,028,000 -20,496,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-08 2019-08-06 2019-11-07 2020-03-30
Assets 22,399,000 40,193,000 33,952,000 26,473,000
Current Assets 14,389,000 32,559,000 26,497,000 19,550,000
Current Liabilities 4,623,000 5,387,000 6,428,000 5,839,000
Equity 12,847,000 29,984,000 22,816,000 16,048,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 12,847,000 29,984,000 22,816,000 16,048,000
Liabilities 9,552,000 10,209,000 11,136,000 10,425,000
Liabilities And Equity 22,399,000 40,193,000 33,952,000 26,473,000
Noncurrent Assets 8,010,000 7,634,000 7,455,000 6,923,000
Noncurrent Liabilities 0 0 4,708,000 4,586,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-08 2019-08-06 2019-11-07 2020-03-30
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 637,000 -1,115,000 -3,290,000 -5,324,000
Net Cash Flow, Continuing 637,000 -1,115,000 -3,290,000 -5,324,000
Net Cash Flow From Financing Activities 165,000 23,865,000 -51,000 23,964,000
Net Cash Flow From Financing Activities, Continuing 165,000 23,865,000 -51,000 23,964,000
Net Cash Flow From Investing Activities 7,973,000 -19,288,000 3,737,000 -2,814,000
Net Cash Flow From Investing Activities, Continuing 7,973,000 -19,288,000 3,737,000 -2,814,000
Net Cash Flow From Operating Activities -7,501,000 -5,692,000 -6,976,000 -26,474,000
Net Cash Flow From Operating Activities, Continuing -7,501,000 -5,692,000 -6,976,000 -26,474,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-08 2019-08-06 2019-11-07 2020-03-30
Comprehensive Income/Loss -7,207,000 -7,148,000 -7,756,000 -29,357,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -7,207,000 -7,148,000 -7,756,000 -29,357,000
Other Comprehensive Income/Loss -7,207,000 -7,148,000 -7,756,000 12,000
Other Comprehensive Income/Loss Attributable To Parent 5,000 24,000 -7,000 12,000
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-08 2019-08-06 2019-11-07 2020-03-30
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -7,212,000 -7,172,000 -7,749,000 -29,369,000
Income/Loss From Continuing Operations Before Tax -7,212,000 -7,172,000 -7,749,000 -29,369,000
Income Tax Expense/Benefit 0 0 0 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -7,213,000 -7,172,000 -7,749,000 -29,369,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -7,212,000 -7,172,000 -7,749,000 -29,369,000
Net Income/Loss Available To Common Stockholders, Basic -7,212,000 -7,172,000 -7,749,000 -29,369,000
Operating Expenses 7,313,000 7,380,000 7,915,000 29,956,000
Operating Income/Loss -7,313,000 -7,380,000 -7,915,000 -29,956,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-09 2018-08-07 2018-11-07 2019-03-29
Assets 45,831,000 42,577,000 38,133,000 30,312,000
Current Assets 44,446,000 37,206,000 30,053,000 21,775,000
Current Liabilities 4,856,000 6,364,000 7,105,000 5,370,000
Equity 40,975,000 32,868,000 26,031,000 19,600,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 40,975,000 32,868,000 26,031,000 19,600,000
Liabilities 4,856,000 9,709,000 12,102,000 10,712,000
Liabilities And Equity 45,831,000 42,577,000 38,133,000 30,312,000
Noncurrent Assets 1,385,000 5,371,000 8,080,000 8,537,000
Noncurrent Liabilities 0 3,345,000 4,997,000 5,342,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-09 2018-08-07 2018-11-07 2019-03-29
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -4,513,000 5,135,000 -4,264,000 -723,000
Net Cash Flow, Continuing -4,513,000 5,135,000 -4,264,000 -723,000
Net Cash Flow From Financing Activities 16,000 12,000 1,210,000 2,515,000
Net Cash Flow From Financing Activities, Continuing 16,000 12,000 1,210,000 2,515,000
Net Cash Flow From Investing Activities 2,400,000 12,579,000 1,404,000 24,688,000
Net Cash Flow From Investing Activities, Continuing 2,400,000 12,579,000 1,404,000 24,688,000
Net Cash Flow From Operating Activities -6,929,000 -7,456,000 -6,878,000 -27,926,000
Net Cash Flow From Operating Activities, Continuing -6,929,000 -7,456,000 -6,878,000 -27,926,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-09 2018-08-07 2018-11-07 2019-03-29
Comprehensive Income/Loss -7,605,000 -9,453,000 -7,425,000 -31,519,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -7,605,000 -9,453,000 -7,425,000 -31,519,000
Other Comprehensive Income/Loss -7,605,000 -9,453,000 -7,425,000 28,000
Other Comprehensive Income/Loss Attributable To Parent -17,000 38,000 9,000 28,000
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-09 2018-08-07 2018-11-07 2019-03-29
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -7,588,000 -9,491,000 -7,434,000 -31,547,000
Income/Loss From Continuing Operations Before Tax -7,588,000 -9,491,000 -7,434,000 -31,547,000
Income Tax Expense/Benefit 0 0 0 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -7,588,000 -9,491,000 -7,434,000 -31,547,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -7,588,000 -9,491,000 -7,434,000 -31,547,000
Net Income/Loss Available To Common Stockholders, Basic -7,588,000 -9,491,000 -7,434,000 -31,547,000
Operating Expenses 7,763,000 9,659,000 7,498,000 31,902,000
Operating Income/Loss -7,763,000 -9,659,000 -7,498,000 -31,902,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2017-08-10 2017-11-09 2018-04-02
Assets UNPUB 15,105,000 59,036,000 52,688,000
Current Assets UNPUB 11,992,000 58,117,000 51,840,000
Current Liabilities UNPUB 5,471,000 5,023,000 4,891,000
Equity UNPUB -120,778,000 54,013,000 47,797,000
Equity Attributable To Noncontrolling Interest UNPUB 0 0 0
Equity Attributable To Parent UNPUB -120,778,000 54,013,000 47,797,000
Liabilities UNPUB 5,471,000 5,023,000 4,891,000
Liabilities And Equity UNPUB 15,105,000 59,036,000 52,688,000
Noncurrent Assets UNPUB 3,113,000 919,000 848,000
Noncurrent Liabilities UNPUB 0 0 0
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2017-08-10 2017-11-09 2018-04-02
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB 4,031,000 -8,852,000
Net Cash Flow, Continuing UNPUB UNPUB 4,031,000 -8,852,000
Net Cash Flow From Financing Activities UNPUB UNPUB 50,702,000 50,591,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB 50,702,000 50,591,000
Net Cash Flow From Investing Activities UNPUB UNPUB -41,435,000 -38,912,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB -41,435,000 -38,912,000
Net Cash Flow From Operating Activities UNPUB UNPUB -5,236,000 -20,531,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -5,236,000 -20,531,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2017-08-10 2017-11-09 2018-04-02
Comprehensive Income/Loss UNPUB -4,923,000 -6,265,000 -22,637,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB -4,923,000 -6,265,000 -22,637,000
Other Comprehensive Income/Loss UNPUB -4,923,000 -6,265,000 -22,637,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -6,000 -33,000
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2017-08-10 2017-11-09 2018-04-02
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB -4,923,000 -6,259,000 -22,604,000
Income/Loss From Continuing Operations Before Tax UNPUB -4,923,000 -6,259,000 -22,604,000
Income Tax Expense/Benefit UNPUB 0 0 UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB -4,923,000 -6,259,000 -22,604,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Net Income/Loss Attributable To Parent UNPUB -4,923,000 -6,259,000 -22,604,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB -4,944,000 -6,259,000 -22,645,000
Operating Expenses UNPUB 4,952,000 6,426,000 23,008,000
Operating Income/Loss UNPUB -4,952,000 -6,426,000 -23,008,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB 21,000 0 41,000
Preferred Stock Dividends And Other Adjustments UNPUB 21,000 0 41,000
Revenues UNPUB 0 0 0
Calendar
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
★
15:30
United States
News Stream
Calendar Calendar of Events
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
GlobeNewswire Inc. • 1w ago
Stocks Financing Agreements
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering
GlobeNewswire Inc. • 2w ago
Stocks Financing Agreements
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering
GlobeNewswire Inc. • 2w ago
News Conference Calls/ Webcasts
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect
GlobeNewswire Inc. • 2w ago
Stocks Earnings Releases and Operating Results
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
Topline results from Phase 1b study of LTI-03, Aileron’s novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024 Topline results from Phase 1b study of LTI-03, Aileron’s novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024
GlobeNewswire Inc. • 3mo ago
Calendar Calendar of Events
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis
GlobeNewswire Inc. • 3mo ago
News News
Top 5 Health Care Stocks That May Collapse In Q2
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70. Here’s the latest list of major overbought players in this sector. TScan Therapeutics, Inc. (NASDAQ: TCRX) TScan Therapeutics and Amgen announced collaboration to identify novel targets in Crohn's disease. The company’s stock has a 52-week high of $6.03 . RSI Value: 77.28 TCRX Price Action: Shares of TScan Therapeutics rose 58.1% to close at $3.40 on Tuesday. Zymeworks Inc. (NASDAQ:
Benzinga • 1y ago
News News
Top 5 Health Care Stocks That May Collapse In Q2
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70. Here’s the latest list of major overbought players in this sector. TScan Therapeutics, Inc. (NASDAQ: TCRX) TScan Therapeutics and Amgen announced collaboration to identify novel targets in Crohn's disease. The company’s stock has a 52-week high of $6.03 . RSI Value: 77.28 TCRX Price Action: Shares of TScan Therapeutics rose 58.1% to close at $3.40 on Tuesday. Zymeworks Inc. (NASDAQ:
Benzinga • 1y ago
News News
Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks Investment Research • 1y ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT